Kodiak Sciences Inc.

Kodiak Sciences Inc. is a biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence ophthalmic diseases. It is committed to protecting vision and is designing and developing novel therapies for the treatment of retinal diseases. The company's ABC Platform is at the heart of its portfolio of retina medicines.

In July 2018, Kodiak initiated its first Phase 1a clinical study of KSI-301, an antibody biopolymer conjugate, in patients with diabetic macular edema (DME).

• 2020.11.17

  Reported2020.11.18

  Kodiak Sciences announces public stock offering[5]Kodiak Sciences宣布公开发行股票prnewswire.com

  Kodiak Sciences announced the pricing of an underwritten public offering of 5,193,237 common shares at $108 per share, with gross proceeds expected to be approximately $560.9 million. The offering was expected to close on or about November 20, 2020, subject to customary closing conditions.

• 2020.04.02

  Reported2020.04.02

  Kodiak Sciences appoints Charles Bancroft to its board[6]Kodiak Sciences 任命查尔斯·班克罗夫特加入董事会prnewswire.com

  Kodiak Sciences announced the appointment of Charles Bancroft to its board of directors.

• 2019.12.19

  Reported2019.12.19

  Kodiak Sciences appoints Taiyin Yang to its board[7]Kodiak Sciences任命Taiyin Yang为董事会成员prnewswire.com

  Kodiak Sciences announced the appointment of Taiyin Yang, Ph.D., to its board of directors.

• 2019.12.03

  Reported2019.12.04

  Kodiak Sciences prices public stock offering[8]Kodiak Sciences确定公开发行股票定价prnewswire.com

  Kodiak Sciences announced the pricing of an underwritten public offering of 6,000,000 common shares at $46 per share, with expected gross proceeds of approximately $276 million before expenses.

• 2019.12.02

  Reported2019.12.02

  Kodiak Sciences announces $225 million royalty funding for KSI-301[9]Kodiak Sciences宣布KSI-301的2.25亿美元特许权使用费融资prnewswire.com

  Kodiak Sciences announced a funding agreement to sell Baker Bros. Advisors a capped royalty right on global net sales of KSI-301 for $225 million in committed development funding. The first $100 million was expected at transaction closing on January 10, 2020, with the remaining $125 million contingent on specified conditions.

Read more

1. 1Next-generation therapies for retinal diseaseskodiak.com
2. 2The ABC Platform - Kodiak Scienceskodiak.com
3. 3Advancing Novel Therapies for Ophthalmic Diseases – Kodiakkodiak.com
4. 4Kodiak Sciences Inc.wikidata.org
5. 5Kodiak Sciences宣布公开发行股票prnewswire.com
6. 6Kodiak Sciences 任命查尔斯·班克罗夫特加入董事会prnewswire.com
7. 7Kodiak Sciences任命Taiyin Yang为董事会成员prnewswire.com
8. 8Kodiak Sciences确定公开发行股票定价prnewswire.com
9. 9Kodiak Sciences宣布KSI-301的2.25亿美元特许权使用费融资prnewswire.com
10. 10Kodiak Sciences Appoints Charles Bancroft to Board of Directorsbiospace.com
11. 11Relmada Therapeutics Announces Pricing of Public Offering of Common Stockprnewswire.com